Jade Biosciences, Inc. (JBIO)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 53/100 (HIGH), 97.2 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 33.55% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
- Jade Biosciences to Participate in Upcoming Conferences
- Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?
- Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
- Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Jade Biosciences Announces Pricing of Public Offering of Common Stock
- Jade Biosciences Announces Proposed Underwritten Public Offering
- Jade Biosciences’ JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney Trials
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Simulating real-world abrocitinib use in atopic dermatitis: results from JADE REAL. — J Dermatolog Treat 2026 Dec PMID 42565345
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Jade Biosciences, Inc..
Full JBIO Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.